$160B Pfizer-Allergan deal seen as costly for consumers, country
A $160 billion deal an- nounced on Monday to merge Pfizer and Allergan and create the world’s biggest drug company renewed the outcry in Washington over “inversions,” in which U.S. corporations combine with companies overseas to lower their tax bills.
The combination — the second-largest merger in history — could have ramifications throughout the globe, pushing up drug prices and spurring more such deals in the fast-consolidating health-care sector and other fields.
It is also increasing the election-year backlash from U.S. politicians who have been blasting drugmakers recently over medicine prices that can exceed $100,000 a year.
In what would be the biggest inversion ever, New York-based Pfizer could save hundreds of millions in U.S. taxes annually because it would move its tax headquarters to Ireland, where Allergan is based. That would enable Pfizer to slash its tax rate from about 25 percent this year to about 18 percent.
Inversions have long been attacked by some politicians as a tax dodge, and Hillary Clinton and Bernie Sanders, the leading Democratic presidential contenders, criticized the deal.
Clinton said it would leave “U.S. taxpayers holding the bag,” while Sanders said it would be a “disaster” for Americans already paying high prescription-drug costs.
Republican presidential candidate Donald Trump said on Monday that “the fact that Pfizer is leaving our country with a tremendous loss of jobs is disgusting.”
Asked if the deal was designed to avoid taxes, Pfizer CEO Ian Read said only that company executives’ obligations are to shareholders and patients.
The merger is subject to approval from regulators in the U.S., European Union and elsewhere. It also needs the go-ahead from shareholders of both companies.
Pfizer makes drugs such as Viagra, cholesterol-lowering Lipitor and the clot-preventer Eliquis. Allergan produces the wrinkle treatment Botox and Restasis for dry eyes, and also has a superior pipeline of medicines in development.
If it goes through, the merger will return Pfizer to the top spot in the pharmaceutical industry after years in which competition from cheaper generics cut into its revenue from some of its blockbuster drugs.
The combination would essentially be Pfizer “but with a lower tax rate,” wrote Bernstein analyst Tim Anderson.
Despite attempts by Congress and the Treasury Department to thwart the practice, about 50 U.S. companies have inverted in the past decade, and more are considering it, according to the nonpartisan Congressional Research Service.
Ireland’s lower corporate tax rate would have saved Pfizer nearly $1 billion of the $3.1 billion in U.S. taxes it paid in 2014.
Sen. Charles Schumer, DN.Y., a member of the Senate Finance Committee, called Pfizer’s move “truly disturbing,” given how the company has benefited from federally funded research and infrastructure. He said Congress needs to reform tax laws, such as by lowering corporate rates, to prevent more inversions.
The health-care sector has been the hottest in U.S. mergers this year and last, with deals worth $451 billion, according to Dealogic.
Drugmakers, insurers and pharmacy chains are combining to boost revenue, cut costs and increase clout in negotiating prices and contracts. Each new deal puts pressure on smaller rivals to bulk up.
John Colley, a professor at Warwick Business School in Britain, predicted even bigger deals as “industry players become concerned about being left behind in the race for scale.”
For consumers, however, such combinations could lead to higher drug prices, as well as higher taxes to cover the lost tax revenue, said Jerry Reisman, a New York merger expert.
“We’re all going to feel this,” he said.